{
    "organizations": [],
    "uuid": "f7c8e0d137e541d07629fe2bd413798b120e6329",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bluebird-bio-and-celgene-corporati/brief-bluebird-bio-and-celgene-corporation-to-co-develop-anti-bcma-car-t-cell-therapy-bb2121-in-the-u-s-idUSFWN1RA0JJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 20 PM / in 2 minutes BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S. Reuters Staff 1 Min Read \n  Bluebird Bio Inc: \n* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES \n* ‍BLUEBIRD AND CELGENE WILL SHARE 50% OF U.S. COSTS AND PROFITS​ \n* ‍BLUEBIRD TO RECEIVE MILESTONES AND ROYALTIES ON EX-U.S. SALES​  ",
    "published": "2018-03-28T15:16:00.000+03:00",
    "crawled": "2018-03-28T15:34:56.038+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "bio",
        "celgene",
        "corporation",
        "car",
        "cell",
        "therapy",
        "bb2121",
        "reuters",
        "staff",
        "min",
        "read",
        "bluebird",
        "bio",
        "inc",
        "bluebird",
        "bio",
        "celgene",
        "corporation",
        "enter",
        "agreement",
        "car",
        "cell",
        "therapy",
        "bb2121",
        "united",
        "state",
        "celgene",
        "share",
        "cost",
        "receive",
        "milestone",
        "royalty"
    ]
}